The distribution ofBRAFgene fusions in solid tumors and response to targeted therapy

Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E-Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience

(2015) Ramona Dadu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease

(2015) Julien Haroche et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containingBRAFkinase fusion

(2015) Alexander M. Menzies et al.   Pigment Cell & Melanoma Research

Activating MET kinase rearrangements in melanoma and Spitz tumours

(2015) Iwei Yeh et al.   Nature Communications

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

(2014) V. Pettirossi et al.   BLOOD

Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein

(2014) Vivek Subbiah et al.   Journal of Hematology & Oncology

Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas

(2014) M. A. Karajannis et al.   NEURO-ONCOLOGY

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas

(2014) Thomas Wiesner et al.   Nature Communications

Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes

(2014) J. Chmielecki et al.   Cancer Discovery

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

(2013) K. E. Hutchinson et al.   CLINICAL CANCER RESEARCH

Pilocytic Astrocytoma

(2013) Zsila Sadighi et al.   JOURNAL OF CHILD NEUROLOGY

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

(2013) David T W Jones et al.   NATURE GENETICS

Clinicopathological relevance of BRAF mutations in human cancer

(2013) Sahar Pakneshan et al.   PATHOLOGY

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy

(2013) Thomas Botton et al.   Pigment Cell & Melanoma Research

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

(2012) J. Haroche et al.   BLOOD

A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation

(2012) Nathan V. Lee et al.   PLoS One

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

(2011) T Yokota et al.   BRITISH JOURNAL OF CANCER

Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease

(2011) A. Vultur et al.   CLINICAL CANCER RESEARCH

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

(2011) Thierry Passeron et al.   EXPERIMENTAL DERMATOLOGY

Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations

(2011) Paul K. Paik et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAFV600E: Implications for Carcinogenesis and Molecular Therapy

(2011) E. R. Cantwell-Dorris et al.   MOLECULAR CANCER THERAPEUTICS

How to apply de Bruijn graphs to genome assembly

(2011) Phillip E C Compeau et al.   NATURE BIOTECHNOLOGY

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes

(2011) Hazem El-Osta et al.   PLoS One

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

(2010) Nallasivam Palanisamy et al.   NATURE MEDICINE

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Targeting the RAF–MEK–ERK pathway in cancer therapy

(2009) Clara Montagut et al.   CANCER LETTERS

Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma

(2009) D T W Jones et al.   ONCOGENE

Tandem Duplication Producing a Novel OncogenicBRAFFusion Gene Defines the Majority of Pilocytic Astrocytomas

(2008) David T.W. Jones et al.   CANCER RESEARCH

AberrantBRAFsplicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma

(2008) Essa Y Baitei et al.   JOURNAL OF PATHOLOGY